We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules

News   Jan 17, 2012

 
LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules
 
 
Advertisement
 

RELATED ARTICLES

Investigational Drug Safely Slows Progression of Diabetic Kidney Disease in Clinical Trial

News

Patients with diabetic kidney disease could potentially be treated with an investigational new drug that may slow the progress of their illness without harmful adverse effects to their hearts, according to the results of a recent global clinical trial.

READ MORE

Inhibitor of Cancer-Causing KRAS Gene Mutation Shrinks Tumors and is Well-Tolerated

News

A novel agent that targets a mutated form of the KRAS gene shrank tumors in most patients in a clinical trial with manageable side effects, researchers reported today.

READ MORE

FDA Approves Remdesivir for COVID-19

News

The US Food and Drug Administration has approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients (≥ 12 years of age and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE